Literature DB >> 11434188

Homocysteine and cardiovascular risk in patients with diabetes mellitus.

Y Yeromenko1, L Lavie, Y Levy.   

Abstract

BACKGROUND AND AIM: Diabetes mellitus is the most common metabolic disorder in the Western world with coronary artery disease as its leading cause of mortality. Conventional coronary risk factors do not explain the high morbidity rate and there is strong evidence linking hyperhomocystinemia and premature atherosclerosis. Therefore, we reviewed the relationship between homocysteine and diabetes mellitus. DATA SYNTHESIS: The literature dealing with diabetes mellitus, B vitamins and metformin was reviewed. Some studies show higher than normal fasting and postmethionine load levels of plasma homocysteine in diabetes patients, particularly in those with nephropathy and microalbuminutia. Metformin use and low plasma B vitamins are other potential mechanisms resulting in hyperhomocysteinemia in these patients.
CONCLUSIONS: Abnormal homocysteine concentration is prevalent in subsets of diabetic patients; its relationship with excess cardiovascular morbidity is not yet clear. Consequently, large prospective studies are essential in order to follow the effects of homocysteine and its normalization on accelerated artherosclerosis in diabetes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11434188

Source DB:  PubMed          Journal:  Nutr Metab Cardiovasc Dis        ISSN: 0939-4753            Impact factor:   4.222


  4 in total

1.  Methylenetetrahydrofolate reductase gene polymorphism, homocysteine and risk of macroangiopathy in Type 2 diabetes mellitus.

Authors:  J Sun; Y Xu; Y Zhu; H Lu
Journal:  J Endocrinol Invest       Date:  2006-10       Impact factor: 4.256

2.  Mild hyperhomocysteinemia and the common C677T polymorphism of methylene tetrahydrofolate reductase gene are not associated with the metabolic syndrome in Type 2 diabetes.

Authors:  G T Russo; A Di Benedetto; E Alessi; R Ientile; A Antico; G Nicocia; R La Scala; E Di Cesare; G Raimondo; D Cucinotta
Journal:  J Endocrinol Invest       Date:  2006-03       Impact factor: 4.256

3.  Menopause modulates homocysteine levels in diabetic and non-diabetic women.

Authors:  G T Russo; A Di Benedetto; E Alessi; A Giandalia; A Gaudio; R Ientile; K V Horvath; B Asztalos; G Raimondo; D Cucinotta
Journal:  J Endocrinol Invest       Date:  2008-06       Impact factor: 4.256

4.  Silent coronary artery disease in type 2 diabetes mellitus: the role of Lipoprotein(a), homocysteine and apo(a) polymorphism.

Authors:  Carmine Gazzaruso; Adriana Garzaniti; Stefano Giordanetti; Colomba Falcone; Pietro Fratino
Journal:  Cardiovasc Diabetol       Date:  2002-11-22       Impact factor: 9.951

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.